BN Business News
Add your company to Business Communicator →

Business · 17/11/20261 min read

Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

First capital increase since relocating global headquarters to Taiwan; Company targets Emerging Stock Board registration by the end of 2027 TAIPEI and EPALINGES, Switzerland and PARIS, Nov. 17, 2026 — Onward Therapeutics, Inc. ("Onward Therapeutics" or the "Company") today...

Original source language: PR Newswire UK — News ReleasesOpen original release →

Explore insights

Business insights →